To announce the press release for material information in a press conference

Date of occurrence of the event:2025/04/23 Company name: OBI Pharma, Inc. Relationship to the Company (please enter ”head office” or ”subsidiaries”):head office Reciprocal shareholding ratios:NA Cause of occurrence: The active cancer immunotherapy Adagloxad Simolenin (OBI-822)/OBI-821, receives its second interim analysis results and the recommendation from the DSMB to terminate the Phase III Triple Negative Breast […]